Teriparatide LA is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase III for Post Menopausal Osteoporosis. According to GlobalData, Phase III drugs for Post Menopausal Osteoporosis have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Teriparatide LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Teriparatide LA overview

SAL-056 (long-acting teriparatide) is under development for the treatment of osteoporosis in postmenopausal women. The drug candidate acts by targeting parathyroid hormone receptor. It is administered through subcutaneous route.

Shenzhen Salubris Pharmaceuticals overview

Shenzhen Salubris Pharmaceuticals (Salubris) focuses on research, development, manufacture and distribution of pharmaceutical products. The company produces and markets medicines to treat diabetes; partial onset seizures; cardiovascular and cerebrovascular indications. It also offers anti-tumor; and anti-infective drugs targeting septicemia, meningitis, respiratory, skin and soft tissue, genital and reproductive system infections. Salubris is investigating small molecules and biologic therapeutics for the treatment of metabolic, oncology, and also bone diseases. The company is also developing interventional medical devices for use in cardiology, cerebrovascular, structural heart, and peripheral vascular disease areas through its subsidiaries. It has operations in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, China.

For a complete picture of Teriparatide LA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.